These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30830576)

  • 1. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
    Das B; Yan R
    CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
    Evin G; Hince C
    Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives.
    Coimbra JRM; Resende R; Custódio JBA; Salvador JAR; Santos AE
    J Alzheimers Dis; 2024; 101(s1):S53-S78. PubMed ID: 38943390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
    Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
    J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
    Kimura A; Hata S; Suzuki T
    J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
    Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
    J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
    Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
    FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.
    Koelsch G
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29027981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
    Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
    Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
    Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
    Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
    Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
    J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
    Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
    J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
    Luo X; Yan R
    Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
    Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
    Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.